Clinical trials: Paclitaxel
Ovarian Carcinoma, Peritoneal Carcinoma
Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer
The purposes of this study are to determine: 1) if treatment with interferon gamma-1b plus standard chemotherapy (carboplatin and paclitaxel) can increase the overall survival of patients with advanced ovarian or primary…
- Trial name
- NCT00047632
- Testing
- Interferon gamma-1b
- Where
- United States
- Volunteers
- 847 people
- Sponsor
- InterMune
Metastatic Melanoma
Taxoprexin® Treatment for Advanced Eye Melanoma
To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population.
- Trial name
- NCT00244816
- Testing
- Taxoprexin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- American Regent, Inc.
Ovarian Cancer, Testicular Germ Cell Tumor
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003518
- Testing
- gemcitabine hydrochloride, paclitaxel
- Where
- 19 sites in United States, South Africa
- Volunteers
- 44 people
- Sponsor
- Eastern Cooperative Oncology Group
Gastric Cancer, Gastroesophageal-junction Cancer
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
Purpose of this study is to define the maximal tolerated dose (MTD) and recommended phase 2 dose (RP2D) of paclitaxel and tepotinib combination therapy in patients with advanced tumors and to evaluate the efficacy of paclitaxel…
- Trial name
- NCT05439993
- Testing
- Tepotinib plus paclitaxel
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Hallym University Medical Center
Breast Cancer
Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005581
- Testing
- cyclophosphamide, epirubicin hydrochloride, fluorouracil
- Where
- 25 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Prostate Cancer
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
The three study drugs (Thalidomide, Taxol, and Estramustine) used in this study are all chemotherapy drugs used in shrinking the cancer.
- Trial name
- NCT00038246
- Testing
- Estramustine, Thalidomide, Paclitaxel (Taxol)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Mixed Tumor, Mullerian
Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
The goal of this clinical research study is to find out if the combination of paclitaxel and carboplatin chemotherapy can shrink or slow the growth of mixed mullerian tumors (MMMT) of the uterus.
- Trial name
- NCT00502203
- Testing
- Carboplatin, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Hypertension, Coronary Artery Disease
Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial
Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was…
- Trial name
- NCT00139386
- Testing
- Candesartan
- Where
- Japan
- Volunteers
- 1,119 people
- Sponsor
- Kumamoto University
Cancer
Real-world Study for the Safety of Albumin-Bound Paclitaxel in Malignant Tumors
This is a multi-center, Prospective, observational study，to evaluate the safety and influencing factors of albumin-bound paclitaxel in the real-world chinese population，and evaluate of the efficacy of albumin-bound paclitaxel in…
- Trial name
- NCT04060290
- Testing
- Observational study
- Where
- 14 sites in China
- Volunteers
- 1,000 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Breast Neoplasms, Metastases, Neoplasm
Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer
Paclitaxel (Taxol, Bristol-Meyers Squibb) has been shown to be very effective against metastatic breast cancer, as well as other cancers.
- Trial name
- NCT00046527
- Testing
- ABI-007
- Where
- United States
- Volunteers
- 460 people
- Sponsor
- Celgene Corporation
Cervical Cancer, Uterine Cancer
Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
Objectives: Primary: To estimate the efficacy of bevacizumab and paclitaxel in patients with recurrent small cell, large cell, and neuroendocrine cervical and uterine cancers, as measured by progression-free survival.
- Trial name
- NCT00626561
- Testing
- Bevacizumab, Paclitaxel
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
Phase I trial to study the effectiveness of paclitaxel, cisplatin, and topotecan with or without filgrastim in treating patients who have newly diagnosed stage III or stage IV epithelial ovarian cancer.
- Conditions
- Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma
- Trial name
- NCT00002913
- Testing
- paclitaxel, cisplatin, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
The goal of this clinical research study is to find the highest tolerable dose of the combination of dasatinib, bevacizumab, and paclitaxel with or without Methylnaltrexone that can be given to patients with advanced cancer.
- Trial name
- NCT01015222
- Testing
- Dasatinib, Bevacizumab, Paclitaxel
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003284
- Testing
- filgrastim, carboplatin, etoposide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Esophageal Cancer
Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis
Taxane-based agents are widely used in the treatment of esophageal squamous cell carcinoma (ESCC). Among these, nab-paclitaxel (albumin-bound paclitaxel) and paclitaxel are the most commonly used.
- Trial name
- NCT07549269
- Testing
- The cohort included 161 patients treated with solvent-based paclitaxel and 226 treated with nanoparticle albumin-bound paclitaxel.
- Where
- 3 sites in China
- Volunteers
- 387 people
- Sponsor
- Sichuan University
Endometrial Cancer, Fallopian Tube Cancer
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma
- Trial name
- NCT00003334
- Testing
- paclitaxel, pegylated liposomal doxorubicin hydrochloride
- Where
- 5 sites in United States
- Sponsor
- NYU Langone Health
Breast Cancer
Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002937
- Testing
- paclitaxel, valspodar
- Where
- 4 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Cancer
A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833
This is a dosage escalation study to estimate the maximum tolerated dose of drug resistance inhibitor PSC 833 given in combination with paclitaxel.
- Conditions
- Breast Cancer, Cancer, Carcinoma, Renal Cell, Lymphoma
- Trial name
- NCT00001383
- Testing
- PSC 833, paclitaxel
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma
Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line
Oral squamous cell carcinoma (OSCC) are considered as a one of the most malignant cancers. It has prognosis due to its distant metastasis and obvious destruction which lead to low survival rate.
- Trial name
- NCT03292822
- Testing
- Licochalcone A, Paclitaxel
- Where
- Egypt
- Volunteers
- 18 people
- Sponsor
- Cairo University
Advanced Cancers
Study of Vemurafenib, Carboplatin, and Paclitaxel
The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with carboplatin and paclitaxel patients with advanced cancer.
- Trial name
- NCT01636622
- Testing
- Vemurafenib, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center